Effects of amlodipine, diltiazem, and verapamil on the anticonvulsant action of topiramate against maximal electroshock-induced seizures in mice

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 3, 2008, Pages 113-121

  Luszczki, Jarogniew J ^a,b   Trojnar, Michal K ^a   Trojnar, Marcin P ^a   Kimber Trojnar, Zaneta ^a   Szostakiewicz, Beata ^a   Zadrozniak, Anna ^a   Borowicz, Kinga K ^a   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Amlodipine; Calcium channel antagonists; Diltiazem; Maximal electroshock seizure test; Pharmacodynamic interaction; Topiramate; Verapamil

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; POLYSORBATE 80; TOPIRAMATE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENTIATION; ELECTRIC SHOCK; LONG TERM MEMORY; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

AMLODIPINE; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BRAIN; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROSHOCK; FLUORESCENCE POLARIZATION IMMUNOASSAY; FRUCTOSE; MICE; MOTOR SKILLS; SEIZURES; VERAPAMIL;

EID: 42149146697     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-007     Document Type: Article

References (51)

1. Angehagen, M., Ben-Menachem, E., Shank, R., Ronnback, L., and Hansson, E. 2004. Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J. Neurochem. 88: 320-325. PMID:14690520.
2. Binnie, C.D., de Beukelaar, F., Meijer, J.W., Meinardi, H., Overweg, J., Wauquier, A., et al. 1985. Open dose-ranging trial of flunarizine as add-on therapy in epilepsy. Epilepsia, 26: 424-428. doi:10.1111/j.1528-1157. 1985.tb05674.x. PMID:3899624.
3. Boissier, J.R., Tardy, J., and Diverres, J.C. 1960. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med. Exp. 3: 81-84.
4. Brodie, M.J., and Schachter, S.C. 2001. Fast Facts. Epilepsy. 2nd ed. Health Press, Oxford.
5. Burges, R., and Moisey, D. 1994. Unique pharmacologic properties of amlodipine. Am. J. Cardiol. 73: A2-A9. doi:10.1016/0002-9149(94)90268-2. PMID:8310972.
6. Cadart, M., Marchand, S., Pariat, C., Bouquet, S., and Couet, W. 2002. Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats. Pharm. Res. 19: 209-214. doi:10.1023/A:1014233102342. PMID:11883649.
7. Czuczwar, S.J., Chodkowska, A., Kleinrok, Z., Malek, U., and Jagiello-Wojtowicz, E. 1990. Effects of calcium channel inhibitors upon the efficacy of common antiepileptic drugs. Eur. J. Pharmacol. 176: 75-83. doi:10.1016/0014-2999(90)90134-R. PMID: 2311661.
8. Czuczwar, S.J., Turski, W.A., and Kleinrok, Z. 1996. Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs. Metab. Brain Dis. 11: 143-152. doi:10.1007/BF02069501. PMID:8776716.
9. Deckers, C.L., Czuczwar, S.J., Hekster, Y.A., Keyser, A., Kubova, H., Meinardi, H., et al. 2000. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia, 41: 1364-1374. doi:10.1111/j.1528-1157.2000.tb00111.x. PMID:11077449.
10. De Falco, F.A., Bartiromo, U., Majello, L., Di Geronimo, G., and Mundo, P. 1992. Calcium antagonist nimodipine in intractable epilepsy. Epilepsia, 33: 343-345. doi:10.1111/j.1528-1157.1992.tb02325.x. PMID:1547764.
11. De Sarro, G.B., Meldrum, B.S., and Nistico, G. 1988. Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br. J. Pharmacol. 93: 247-256. PMID:3359104.
12. Dodgson, S.J., Shank, R.P., and Maryanoff, B.E. 2000. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia, 41(Suppl 1): S35-S39. doi:10.1111/j.1528-1157.2000.tb06047.x. PMID:10768298.
13. Furukawa, T., Nukada, T., Suzuki, K., Fujita, Y., Mori, Y., Nishimura, M., et al. 1997. Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br. J. Pharmacol. 121: 1136-1140. doi:10.1038/sj.bjp. 0701226. PMID:9249249.
14. Furukawa, T., Yamakawa, T., Midera, T., Sagawa, T., Mori, Y., and Nukada, T. 1999. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 291: 464-473. PMID:10525060.
15. Heinemann, U., and Hamon, B. 1986. Calcium and epileptogenesis. Exp. Brain Res. 65: 1-10. doi:10.1007/BF00243826. PMID:3026832.
16. Hinkle, D.E., Wiersma, W., and Jurs, S.G. 1994. Applied statistics for the behavioral science. 3rd ed. Houghton Mifflin Company, Boston.
17. Jagiello-Wojtowicz, E., Czuczwar, S.J., Chodkowska, A., Szponar, J., and Kleinrok, Z. 1991. Influence of calcium channel blockers on pentylenetetrazol and electroshock-induced convulsions in mice. Pol. J. Pharmacol. Pharm. 43: 95-101. PMID:1946038.
18. Kaminski, R., Jasinski, M., Jagiello-Wojtowicz, E., Kleinrok, Z., and Czuczwar, S.J. 1999. Effect of amlodipine upon the protective activity of antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol. Res. 40: 319-325. doi:10.1006/phrs.1999.0518. PMID: 10527643.
19. Karler, R., Calder, L.D., and Turkanis, S.A. 1991. Calcium channel blockers and excitatory amino acids. Brain Res. 551: 331-333. doi:10.1016/0006-8993(91)90952-R. PMID: 1913163.
20. Köhling, R., Lehmenkukhler, A., Nicholson, C., and Speckmann, E.J. 1993. Superfusion of verapamil on the cerebral cortex does not suppress epileptic discharges due to restricted diffusion (rats, in vivo). Brain Res. 626: 149-155. doi:10.1016/0006-8993(93)90574-7. PMID:8281426.
21. Kulak, W., Sobaniec, W., Wojtal, K., and Czuczwar, S.J. 2004. Calcium modulation in epilepsy. Pol. J. Pharmacol. 56: 29-41. PMID:15047975.
22. Laskey, A.L., Korn, D.E., Moorjani, B.I., Patel, N.C., and Tobias, J.D. 2000. Central hyperventilation related to administration of topiramate. Pediatr. Neurol. 22: 305-308. doi:10.1016/S0887-8994(99)00143-5. PMID:10788749.
23. Litchfield, J.T., and Wilcoxon, F. 1949. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96: 99-113. PMID:18152921.
24. Löscher, W., Fassbender, C.P., and Nolting, B. 1991. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 8: 79-94. doi:10.1016/0920-1211(91)90075-Q. PMID:2065646.
25. Luszczki, J.J., and Czuczwar, S.J. 2004. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia, 45: 895-907. doi:10.1111/j.0013-9580.2004.05104.x. PMID: 15270754.
26. Luszczki, J.J., and Czuczwar, S.J. 2005. How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol. Rep. 57: 782-786. PMID:16382197.
27. Luszczki, J.J., and Czuczwar, S.J. 2007. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31: 529-538. doi:10.1016/j.pnpbp.2006.11.020. PMID:17204358.
28. Luszczki, J.J., Borowicz, K.K., Swiader, M., and Czuczwar, S.J. 2003a. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia, 44: 489-499. doi:10.1046/j.1528-1157.2003.32702.x. PMID:12680997.
29. Luszczki, J.J., Swiader, M., Czuczwar, M., Kis, J., and Czuczwar, S.J. 2003b. Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol. Biochem. Behav. 75: 319-327. doi:10.1016/S0091-3057(03)00081-9. PMID:12873622.
30. Luszczki, J.J., Wojcik-Cwikla, J., Andres, M.M., and Czuczwar, S.J. 2005. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology, 30: 958-973. doi:10.1038/sj.npp.1300602. PMID:15525996.
31. Luszczki, J.J., Ratnaraj, N., Patsalos, P.N., and Czuczwar, S.J. 2006a. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch. Pharmacol. 373: 169-181. doi:10.1007/s00210-006-0055-4. PMID:16604339.
32. Luszczki, J.J., Mohamed, M., and Czuczwar, S.J. 2006b. 2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Eur. J. Pharmacol. 531: 66-73. doi:10.1016/j.ejphar.2005.11.045. PMID:16403497.
33. Marinho, M.M., de Bruin, V.M., de Sousa, F.C., Aguiar, L.M., de Pinho, R.S., and Viana, G.S. 1997. Inhibitory action of a calcium channel blocker (nimodipine) on seizures and brain damage induced by pilocarpine and lithium-pilocarpine in rats. Neurosci. Lett. 235: 13-16. doi:10.1016/S0304-3940(97)00687-3. PMID:9389584.
34. Meldrum, B. 2002. Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs. Epilepsy Res. 50: 33-40. doi:10.1016/S0920-1211(02)00066-9. PMID:12151115.
35. Meyer, F.B., Anderson, R.E., Sundt, T.M., and Sharbrough, F.W. 1986. Selective central nervous system calcium channel blockers-a new class of anticonvulsant agents. Mayo Clin. Proc. 61: 239-247. PMID:3951256.
36. Meyer, F.B., Anderson, R.E., Sundt, T.M., Yaksh, T.L., and Sharbrough, F.W. 1987. Suppression of pentylenetetrazole seizures by oral administration of a dihydropyridine Ca2+ antagonist. Epilepsia, 28: 409-414. doi:10.1111/j.1528-1157.1987.tb03666.x. PMID:3622416.
37. Miljanich, G.P., and Ramachandran, J. 1995. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 35: 707-734. doi:10.1146/annurev.pa.35.040195.003423. PMID: 7598513.
38. Nakane, Y., Seino, M., Yagi, A., Kaji, S., and Yamauchi, T. 1989. Effects of flunarizine therapy on intractable epilepsy. Arzneimittelforschung, 39: 793-798. PMID:2675853.
39. Overweg, J., Binnie, C.D., Meijer, J.W., Meinardi, H., Nuijten, S.T., Schmaltz, S., et al. 1984. Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy. Epilepsia, 25: 217-222. doi:10.1111/j.1528-1157.1984.tb04178.x. PMID:6705752.
40. Page, R.L., 2nd, and Bainbridge, J.L. 2006. Intractable epistaxis associated with topiramate administration. Ann. Pharmacother. 40: 1462-1465. doi:10.1345/aph.1H078. PMID:16822894.
41. Pahor, M., Guralnik, J.M., Furberg, C.D., Carbonin, P., and Havlik, R. 1996. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet, 347: 1061-1065. doi:10.1016/S0140-6736(96)90276-7. PMID:8602055.
42. Shank, R.P., Gardocki, J.F., Streeter, A.J., and Maryanoff, B.E. 2000. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia, 41(Suppl 1): S3-S9. doi:10.1111/j.1528-1157.2000.tb06045.x. PMID:10768292.
43. Shank, R.P., Doose, D.R., Streeter, A.J., and Bialer, M. 2005. Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res. 63: 103-112. doi:10.1016/j.eplepsyres.2005.01.001. PMID:15715969.
44. Starreveld, E., de Beukelaar, F., Wilson, A.F., McLean, D.R., and Findlay, H.P. 1989. Double-blind cross-over placebo controlled study of flunarizine in patients with therapy resistant epilepsy. Can. J. Neurol. Sci. 16: 187-190. PMID:2731086.
45. Straka, R.J., Swanson, A.L., and Parra, D. 1998. Calcium channel antagonists: morbidity and mortality-what's the evidence? Am. Fam. Physician, 57: 1551-1560. PMID: 9556644.
46. Thomas, J. 1990. The effect of nimodipine on picrotoxin-induced seizures. Brain Res. Bull. 24: 11-15. doi:10.1016/0361-9230(90)90283-6. PMID:2310938.
47. Venault, P., Chapouthier, G., de Carvalho, L.P., Simiand, J., Morre, M., Dodd, R.H., et al. 1986. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature, 321: 864-866. doi:10.1038/321864a0. PMID:3724846.
48. Vergouwen, M.D., Vermeulen, M., de Haan, R.J., Levi, M., and Roos, Y.B. 2007. Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review. J. Cereb. Blood Flow Metab. 27: 1293-1308. doi:10.1038/sj.jcbfm.9600431. PMID:17191079.
49. Wilner, A., Raymond, K., and Pollard, R. 1999. Topiramate and metabolic acidosis. Epilepsia, 40: 792-795. doi:10.1111/j.1528-1157.1999.tb00781.x. PMID:10368081.
50. Wurpel, J.N., and Iyer, S.N. 1994. Calcium channel blockers verapamil and nimodipine inhibit kindling in adult and immature rats. Epilepsia, 35: 443-449. doi:10.1111/j.1528-1157.1994.tb02458.x. PMID:8156971.
51. Zhang, X., Velumian, A.A., Jones, O.T., and Carlen, P.L. 2000. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia, 41(Suppl 1): S52-S60. doi:10.1111/j.1528-1157. 2000.tb02173.x. PMID:10768302.